.25 mg of semaglutide Oral Wegovy approved for obesity management by FDA on December 23, 2025 Formulation: High‑dose oral (25 daily) — previously only available as weekly injections. Indication: Adults with obesity (BMI ≥30) Oral Wegovy Approved | Medical

Both semaglutide and lipotropic compounds increase metabolic turnover and fluid demand

Some colors are perfectly normal

BPC-157 (5mg) Description A single-component research material supplied for controlled research environments

Bioelectrical impedance (InBody, smart scales)

Results: Oral semaglutide reduced HbA1c levels compared to placebo Oral semaglutide patients experienced significant weight loss compared to those on placebo The primary outcome (composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) occurred in 3.8% of patients in the oral semaglutide group and 4.8% in the placebo group, which showed that cardiovascular safety of oral semaglutide was non-inferior to placebo